NYSE$OGN
Organon & Co. · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Organon's first quarter results for 2022 showed revenue growth and improved profitability.
Organon reported a solid start to the year with a 4% increase in total net revenue, reaching $1,567 million. The company saw growth in Biosimilars and Established Brands, while Women's Health experienced a slight decline. Adjusted EBITDA margin improved to 41.3%.
- Total net revenue increased by 4% as-reported and 8% ex-FX compared to Q1 2021.
- Women's Health declined 5% as-reported and 3% ex-FX, impacted by Nuvaring and Nexplanon.
- Biosimilars revenue grew 22% as-reported and 25% ex-FX, driven by Renflexis and Ontruzant.
- Established Brands revenue increased 10% as-reported and 15% ex-FX, benefiting from demand fluctuations and volume growth.
Headline financials
Revenue & EPS history
Organon · Revenue · Quarterly
$1.57B
Revenue by segment
Organon · $1.57B total across 4 segments · Q1 2022
- Established Brands$1B+9.6%63.9%
- Women's Health$401M-5.0%25.6%
- Biosimilars$128M+21.9%8.2%
- Other$36M-2.7%2.3%
Forward guidance
Organon affirmed the full year 2022 financial guidance previously provided on February 17, 2022, which is presented on a non-GAAP basis.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-0.9%
Avg return
Earnings day
-1.6%
Avg return
5 days after
-4.8%
Avg return
30 days after
40%
10 / 25 earnings
Positive
+14.4%
Q4 2023
Best reaction
-26.9%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.6% | +0.1% | +0.1% | |
| Q4 2025 | -8.2% | -5.3% | -17.4% | |
| Q3 2025 | +14.0% | +11.1% | +5.9% | |
| Q1 2025 | -26.9% | -29.4% | -28.7% | |
| Q4 2024 | +11.0% | +5.3% | +4.1% | |
| Q3 2024 | +0.8% | -8.2% | -11.5% | |
| Q2 2024 | -5.6% | -0.2% | +5.8% | |
| Q1 2024 | +4.1% | +8.3% | +13.3% | |
| Q4 2023 | +14.4% | +13.0% | +11.7% | |
| Q3 2023 | -9.2% | -15.3% | -21.5% | |
| Q2 2023 | +6.2% | +6.2% | -10.7% | |
| Q1 2023 | -7.1% | -12.4% | -18.5% | |
| Q4 2022 | -11.1% | -7.6% | -25.9% | |
| Q3 2022 | -6.1% | -9.1% | +3.0% | |
| Q2 2022 | -3.3% | -3.6% | -12.5% | |
| Q1 2022 | +4.8% | +4.7% | +12.0% | |
| Q4 2019 | +0.8% | -0.3% | -4.9% | |
| Q4 2021 | -0.7% | -1.0% | -3.5% | |
| Q3 2020 | -3.9% | -5.1% | -17.2% | |
| Q3 2021 | -8.0% | -8.4% | -21.5% | |
| Q2 2020 | +3.4% | -2.9% | -1.4% | |
| Q2 2021 | +14.3% | +18.2% | +13.2% | |
| Q4 2020 | -1.5% | +0.7% | +1.6% | |
| Q1 2020 | -1.5% | +0.7% | +1.6% | |
| Q1 2021 | -1.5% | +0.7% | +1.6% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro